Mizuho raised the firm’s price target on EyePoint (EYPT) to $36 from $33 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EyePoint appoints Campbell as Chief Commercial Officer
- EyePoint reports inducement grants under NASDAQ listing rule
- EyePoint Pharmaceuticals: Advancing DURAVYU Phase 3 Programs with Strong Cash Runway Supports Buy Rating and $23 Target
- EyePoint reports corporate update, 2026 anticipated milestones for DURAVYU